CN114096272B - mRNA制剂 - Google Patents

mRNA制剂 Download PDF

Info

Publication number
CN114096272B
CN114096272B CN202080038101.1A CN202080038101A CN114096272B CN 114096272 B CN114096272 B CN 114096272B CN 202080038101 A CN202080038101 A CN 202080038101A CN 114096272 B CN114096272 B CN 114096272B
Authority
CN
China
Prior art keywords
mrna
combination
pseudouridine
trimix
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080038101.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114096272A (zh
Inventor
S·德科克
S·贝维尔斯
P·汤米
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ezer Arne Immunotherapy Co ltd
Universite Libre de Bruxelles ULB
Original Assignee
Ezer Arne Immunotherapy Co ltd
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ezer Arne Immunotherapy Co ltd, Universite Libre de Bruxelles ULB filed Critical Ezer Arne Immunotherapy Co ltd
Publication of CN114096272A publication Critical patent/CN114096272A/zh
Application granted granted Critical
Publication of CN114096272B publication Critical patent/CN114096272B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080038101.1A 2019-04-26 2020-04-24 mRNA制剂 Active CN114096272B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
EP19171323.9 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (2)

Publication Number Publication Date
CN114096272A CN114096272A (zh) 2022-02-25
CN114096272B true CN114096272B (zh) 2024-08-06

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038101.1A Active CN114096272B (zh) 2019-04-26 2020-04-24 mRNA制剂

Country Status (12)

Country Link
US (1) US20220362360A1 (https=)
EP (1) EP3958893A1 (https=)
JP (1) JP7650001B2 (https=)
KR (1) KR20220023340A (https=)
CN (1) CN114096272B (https=)
AU (1) AU2020263948A1 (https=)
BR (1) BR112021021262A2 (https=)
CA (1) CA3138011A1 (https=)
IL (1) IL287560B2 (https=)
MX (1) MX2021013018A (https=)
SG (1) SG11202111720TA (https=)
WO (1) WO2020216911A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386843A1 (en) * 2019-01-04 2021-12-16 Etherna Immunotherapies Nv mRNA Vaccine
WO2020182993A1 (en) * 2019-03-13 2020-09-17 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201100A1 (en) * 2007-09-14 2010-06-30 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476419B2 (en) * 2007-09-14 2013-07-02 Vrije Universiteit Brussel Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
CN120842296A (zh) * 2015-09-21 2025-10-28 垂林克生物技术有限公司 用于合成5’-加帽rna的组合物和方法
EP3359670B2 (en) * 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2201100A1 (en) * 2007-09-14 2010-06-30 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination

Also Published As

Publication number Publication date
IL287560B1 (en) 2025-10-01
BR112021021262A2 (pt) 2021-12-21
EP3958893A1 (en) 2022-03-02
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
CA3138011A1 (en) 2020-10-29
IL287560A (en) 2021-12-01
IL287560B2 (en) 2026-02-01
WO2020216911A1 (en) 2020-10-29
SG11202111720TA (en) 2021-11-29
KR20220023340A (ko) 2022-03-02
CN114096272A (zh) 2022-02-25
JP7650001B2 (ja) 2025-03-24
JP2022532038A (ja) 2022-07-13
MX2021013018A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
Shi et al. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Hager et al. Nucleic acid-based approaches for tumor therapy
Fu et al. mRNA vaccines in the context of cancer treatment: from concept to application
CN109331176B (zh) 用于免疫治疗的rna制剂
CN114096272B (zh) mRNA制剂
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
US20240216493A1 (en) Cancer therapy compositions and uses thereof
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
Shariati et al. mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Wang et al. Engineered virus-mimicking nanovaccine with lymph node–tumor dual-targeting and STING-activating capacity for robust cancer immunotherapy
CN119563028A (zh) 具有分泌抗原和免疫调节物的合成自扩增mRNA分子
KR20250130586A (ko) Hpv 감염-관련 질병을 예방 또는 치료하기 위한 폴리뉴클레오티드 분자
EP4561536A1 (en) Loaded extracellular vesicle
AU2022422532A1 (en) Immunostimulatory mrna compositions and uses thereof
Huang et al. mRNA vaccines as cancer therapies
WO2025140126A1 (en) Therapeutic ly6k mrna vaccine for cancer
JP2023502925A (ja) 生体内遺伝子治療のためのポリマー封入ウイルスベクター
JP2026512425A (ja) 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
HK40068420A (en) Mrna formulation
HK40068420B (zh) Mrna制剂
Cui et al. From Design to Clinical Use: mRNA Vaccines for Infectious Diseases and Cancer
WO2025146130A1 (en) Therapeutic BIRC5 mRNA Vaccine for Cancer
WO2024020453A2 (en) Immune system modulators and uses thereof
JP2026513549A (ja) 標的化脂質ナノ粒子の合成方法及びその使用
Moon Engineering Multi-Action Lipid Nanoparticle Platforms for Cancer Immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068420

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20220921

Address after: Belgium Neal

Applicant after: Ezer Arne immunotherapy Co.,Ltd.

Applicant after: UNIVERSITE LIBRE DE BRUXELLES

Address before: Belgium Neal

Applicant before: Ezer Arne immunotherapy Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant